Phaseline

Companies › Primmune Therapeutics

Primmune Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PRTX007
TLR7 agonist prodrug (prodrug of PRX034)
TLR7Phase 2Melanoma Stage IIIDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07565285PRTX007Phase 2Melanoma Stage IIIOncologyDec 2027

Targets

TLR7 (1)

Companies with the same targets

Merck KGaA Eikon Therapeutics United Immunity Beeline Medicines OX2 Therapeutics HighField Biopharmaceuticals Ascendis Pharma Oncology Division Bolt Biotherapeutics Inimmune

Companies built like this

Vasgene Therapeutics Suzhou BlueHorse Therapeutics Pieris Pharmaceuticals Evaxion Biotech Tessa Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.